Advertisement
Screener

Dyne Therapeutics, Inc. (DYN) Graph

DYN Revenue Flow

A current filed revenue breakdown could not be established from the retained filing evidence.

  • 2026-06-30: Research and development $152.17M; Operating expenses $181.66M; Net income -$178.56M.
  • 2026-03-31: Research and development $100.89M; Operating expenses $125.28M; Net income -$120.85M.
  • 2025-12-31: Research and development $95.43M*; Operating expenses $116.13M*; Net income $334.26M*.
  • 2025-09-30: Research and development $97.22M; Operating expenses $113.89M; Net income -$108.04M.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endResearch and developmentOperating expensesNet income
2026-06-30$152.17M$181.66M-$178.56M
2026-03-31$100.89M$125.28M-$120.85M
2025-12-31$95.43M*$116.13M*$334.26M*
2025-09-30$97.22M$113.89M-$108.04M
2025-06-30$99.24M$115.79M-$110.86M
2025-03-31$106.45M$122.37M-$115.36M
2024-09-30$92.80M$105.66M-$97.13M
2024-06-30$62.26M$71.96M-$65.10M
2024-03-31$44.54M$69.16M-$65.65M
2023-09-30$55.25M$62.27M-$60.21M
2023-06-30$59.13M$66.74M-$64.90M
2023-03-31$37.54M$45.46M-$44.19M
2022-09-30$34.67M$42.28M-$41.38M
2022-06-30$46.66M$52.76M-$52.30M
2022-03-31$28.24M$35.78M-$35.58M
2021-09-30$36.51M$42.77M-$42.58M
2021-06-30$23.87M$30.16M-$29.95M
2021-03-31$18.63M$25.13M-$24.97M
2020-09-30$9.68M$13.52M-$13.92M
2020-06-30$7.33M$8.68M-$8.98M
2020-03-31$6.09M$7.85M-$7.89M
2019-09-30$2.98M$3.63M-$5.87M
2019-06-30(m)(m)-$1.50M
2019-03-31(m)(m)-$2.09M

Revenue and expense 6 month

Period endResearch and developmentOperating expensesNet income
2026-06-30$253.18M$306.94M-$299.41M
2025-06-30$205.68M$238.16M-$226.22M
2024-06-30$106.80M$141.12M-$130.75M
2023-06-30$96.67M$112.20M-$109.09M
2022-06-30$74.90M$88.54M-$87.89M
2021-06-30$42.50M$55.30M-$54.92M
2020-06-30$13.42M$16.53M-$16.87M

Revenue and expense 9 month

Period endResearch and developmentOperating expensesNet income
2025-09-30$302.90M$352.06M-$334.26M
2024-09-30$199.60M$246.78M-$227.88M
2023-09-30$151.92M$174.47M-$169.30M
2022-09-30$109.57M$130.82M-$129.27M
2021-09-30$79.01M$98.06M-$97.50M
2020-09-30$23.10M$30.05M-$30.79M
2019-09-30$6.78M$8.36M-$9.46M

Revenue and expense 12 month

Period endResearch and developmentOperating expensesIncome taxNet income
2025-12-31$398.33M$468.18M$0.00-$446.20
2024-12-31$281.41M$343.89M$0.00-$317.40
2023-12-31$210.76M$242.16M$0.00-$235.90
2022-12-31$142.76M$170.96M(m)-$168.10
2021-12-31$121.31M$150.03M(m)-$149.29M
2020-12-31$45.20M$58.65M(m)-$59.44M
2019-12-31$11.04M$13.83M(m)-$14.86M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Arcus Biosciences, Inc. (RCUS)United States$3.188B-8.52
Arcutis Biotherapeutics, Inc. (ARQT)United States$3.303B115.47
Enliven Therapeutics, Inc. (ELVN)United States$3.307B-35.07
Amylyx Pharmaceuticals, Inc. (AMLX)United States$3.361B-13.15
PRECIGEN, INC. (PGEN)United States$2.757B-12.94
NewAmsterdam Pharma Co N.V. (NAMS)$2.719B-15.37
MBX Biosciences, Inc. (MBX)United States$2.664B-25.36
IDEAYA Biosciences, Inc. (IDYA)United States$3.540B-20.52
Organon & Co. (OGN)United States$3.603B17.03
Disc Medicine, Inc. (IRON)United States$2.553B-11.40